Rebamipide abolishes Helicobacter pylori CagA-induced phospholipase D1 expression via inhibition of NFκB and suppresses invasion of gastric cancer cells

Oncogene

Volumn 32, Issue 30, 2013, Pages 3531-3542

  Kang, D W ^a   Hwang, W C ^a   Park, M H ^a   Ko, G H ^b   Ha, W S ^b   Kim, K S ^c   Lee, Y C ^c   Choi, K Y ^d   Min, D S ^a,d  

^a Pusan National University   (South Korea)

^b Gyeongsang National University School of Medicine   (South Korea)

^c Dong A University   (South Korea)

^d Yonsei University   (South Korea)

Author keywords

CagA; Gastric cancer; Helicobacter pylori; NF B; Phospholipase D1; Rebamipide

Indexed keywords

ACTIVATION INDUCED CYTIDINE DEAMINASE; CAGA PROTEIN; GELATINASE B; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 8; PHOSPHOLIPASE D1; REBAMIPIDE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CELL INVASION; CONTROLLED STUDY; DRUG MECHANISM; ENZYME ACTIVITY; HELICOBACTER PYLORI; HUMAN; HUMAN CELL; HUMAN TISSUE; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; STOMACH CANCER;

ALANINE; ANTI-ULCER AGENTS; ANTIGENS, BACTERIAL; BACTERIAL PROTEINS; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HELICOBACTER PYLORI; HUMANS; NEOPLASM INVASIVENESS; NF-KAPPA B; PHOSPHOLIPASE D; QUINOLONES; STOMACH NEOPLASMS; UP-REGULATION;

HELICOBACTER PYLORI;

EID: 84880920129     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2012.358     Document Type: Article

References (59)

1. Hatakeyama M. Linking epithelial polarity and carcinogenesis by multitasking Helicobacter pylori virulence factor CagA. Oncogene 2008; 27: 7047-7054.
2. Hatakeyama M. Oncogenic mechanisms of the Helicobacter pylori CagA protein. Nat Rev Cancer 2004; 4: 688-694. (Pubitemid 39215067)
3. Covacci A, Censini S, Bugnoli M, Petracca R, Burroni D, Macchia G et al. Molecular characterization of the 128-kDa immunodominant antigen of Helicobacter pylori associated with cytotoxicity and duodenal ulcer. Proc Natl Acad Sci USA 1993; 90: 5791-5795. (Pubitemid 23176248)
4. Blaser MJ, Perez-Perez GI, Kleanthous H. Infection with Helicobacter pylori strains possessing cagA is associated with an increased risk of developing adenocarcinoma of the stomach. Cancer Res 1995; 55: 2111-2115.
5. Huang JQ, Zheng GF, Sumanac K, Irvine EJ, Hunt RH. Meta-analysis of the relationship between cagA seropositivity and gastric cancer. Gastroenterology 2003; 125: 1636-1644. (Pubitemid 37500427)
6. Parsonnet J, Friedman GD, Orentreich N, Vogelman H. Risk for gastric cancer in people with CagA positive or CagA negative Helicobacter pylori infection. Gut 1997; 40: 297-301. (Pubitemid 27145639)
7. Foryst-Ludwig A, Naumann M. p21-activated kinase 1 activates the nuclear factor kappa B (NFκB)-inducing kinase-Ikappa B kinases NFκB pathway and proinflammatory cytokines in Helicobacter pylori infection. J Biol Chem 2000; 275: 39779-39785. (Pubitemid 32059009)
8. Brandt S, Kwok T, Hartig R, Konig W, Backert S. NFκB activation and potentiation of proinflammatory responses by the Helicobacter pylori CagA protein. Proc Natl Acad Sci USA 2005; 102: 9300-9305. (Pubitemid 40923558)
9. Lamb A, Yang XD, Tsang YH, Li JD, Higashi H, Hatakeyama M et al. Helicobacter pylori CagA activates NFκB by targeting TAK1 for TRAF6-mediated Lys 63 ubiquitination. EMBO Rep 2009; 10: 1242-1249.
10. Shurmu SA, Tummuru MK, Miller GG, Bluser MJ. Interleukin-8 response of gastric epithelial cell lines to Helicobacter pylori stimulation in vitro. Infect Immun 1995; 63: 1681-1687.
11. Censini S, Lange C, Xiang Z, Crabtree JE, Ghiara P, Borodovsky M. cag, a pathogenicity island of Helicobacter pylori, encodes type I-specific and disease-associated virulence factors. Proc Natl Acad Sci USA 1996; 93: 14648-14653.
12. Maeda S, Yoshida H, Ogura K, Mitsuno Y, Hirata Y, Yamaji Y et al. H. pylori activates NF-kappaB through a signaling pathway involving IkappaB kinases, NF-kappa Binducing kinase, TRAF2, and TRAF6 in gastric cancer cells. Gastroenterology 2000; 119: 97-108. (Pubitemid 30452583)
13. Peek Jr RM. Orchestration of aberrant epithelial signaling by Helicobacter pylori CagA. Sci STKE 2005 pe14.
14. Ohnishi N, Yuasa H, Tanaka S, Sawa H, Miura M, Matsui A. Transgenic expression of Helicobacter pylori CagA induces gastrointestinal and hematopoietic neoplasms in mouse. Proc Natl Acad Sci USA 2008; 105: 1003-1008. (Pubitemid 351282071)
15. Su W, Chen Q, Frohman MA. Targeting phospholipase D with small molecule inhibitors as a potential therapeutic approach for cancer metastasis. Future Oncol 2009; 5: 1477-1486.
16. Huang P, Frohman MA. The potential for phospholipase D as a new therapeutic target. Expert Opin Ther Targets 2007; 11: 707-716. (Pubitemid 46730084)
17. Su W, Chen Q, Frohman MA. Targeting phospholipase D with small molecule inhibitors as a potential therapeutic approach for cancer metastasis. Future Oncol 2009; 5: 1477-1486.
18. Kang DW, Park MH, Lee YJ, Kim HS, Kwon TK, Park WS et al. Phorbol ester up-regulates phospholipase D1 but not phospholipase D2 expression through a PKC/Ras/ERK/NFκB-dependent pathway and enhances matrix metalloproteinase-9 secretion in colon cancer cells. J Biol Chem 2008; 283: 4094-4104.
19. Kang DW, Min G, Park do Y, Hong KW, Min DS. Rebamipide-induced downregulation of phospholipase D inhibits inflammation and proliferation in gastric cancer cells. Exp Mol Med 2010; 42: 555-564.
20. Kang DW, Park MH, Lee YJ, Kim HS, Lindsley CW, Alex Brown H et al. Autoregulation of phospholipase D activity is coupled to selective induction of phospholipase D1 expression to promote invasion of breast cancer cells. Int J Cancer 2011; 128: 805-816.
21. Arakawa T, Kobayashi K, Yoshikawa T, Tarnawski A. Rebamipide: overview of its mechanisms of action and efficacy in mucosal protection and ulcer healing. Dig Dis Sci 1998; 43: S5-S13.
22. Arakawa T, Higuchi K, Fujiwara Y, Watanabe T, Tominaga K, Sasaki E et al. 15th anniversary of rebamipide: looking ahead to the new mechanisms and new applications. Dig Dis Sci 2005; 50: S3-S11. (Pubitemid 41380792)
23. Yoshida N, Yoshikawa T, Iinuma S, Arai M, Takenaka S, Sakamoto K et al. Rebamipide protects against activation of neutrophils by Helicobacter pylori. Dig Dis Sci 1996; 41: S1139-S1144.
24. Tarnawski A, Pai R, Chiou SK, Chai J, Chu EC. Rebamipide inhibits gastric cancer growth by targeting survivin and Aurora-B. Biochem Biophys Res Commun 2005; 334: 207-212. (Pubitemid 40978527)
25. Kishimoto S, Haruma K, Tari A, Sakurai K, Nakano M, Y Nakagawa. Rebamipide an antiulcer drug, prevents DSS-induced colitis formation in rats. Dig Dis Sci 2000; 45: S1608-S1616.
26. Suzuki M, Mimuro H, Kiga K, Fukumatsu M, Ishijima N, Morikawa H et al. Helicobacter pylori CagA phosphorylation-independent function in epithelial proliferation and inflammation. Cell Host Microbe 2009; 5: 23-34.
27. Kang DW, Min DS. Platelet derived growth factor increases phospholipase D1 but not phospholipase D2 expression via NFκB signaling pathway and enhances invasion of breast cancer cells. Cancer Lett 2010; 294: 125-133.
28. Sier CF, Kubben FJ, Ganesh S, Heerding MM, Griffioen G, Hanemaaijer R et al. Tissue levels of matrix metalloproteinases MMP-2 and MMP-9 are related to overall survival of patients with gastric carcinomas. Br J Cancer 1996; 74: 413-417. (Pubitemid 26254571)
29. Zhang XY, Chan WY, Whitney BM, Fan DM, Chow JH, Liu Y et al. Changes of interleukin expression correlate with Helicobacter pylori infection and lymph node metastases in gastric carcinoma. Diagn Mol Pathol 2002; 11: 135-139.
30. Ramos-DeSimone N, Hahn-Dantona E, Sipley J, Nagase H, Frech DL, Quigley JP. Activation of matrix metalloproteinase 9 (MMP-9) via a converging plasmin/stromelysin-1 cascade enhances tumor cell invasion. J Biol Chem 1999; 274: 13066-13077.
31. Mori N, Sato H, Hayashibara T, Senba M, Geleziunas R, Wada A et al. Helicobacter pylori induces matrix metalloproteinase-9 through activation of NFκB. Gastroenterology 2003; 124: 983-992. (Pubitemid 36389801)
32. Matsumoto Y, Marusawa H, Kinoshita K, Endo Y, Kou T, Morisawa T et al. Helicobacter pylori infection triggers aberrant expression of activation-induced cytidine deaminase in gastric epithelium. Nat Med 2007; 13: 470-476. (Pubitemid 46559833)
33. Peek Jr RM, Blaser MJ. Helicobacter pylori and gastrointestinal tract adenocarcinomas. Nat Rev Cancer 2002; 2: 28-37. (Pubitemid 37328805)
34. Polk DB, Peek Jr RM. Helicobacter pylori: gastric cancer and beyond. Nat Rev Cancer 2010; 10: 403-414.
35. Min DS, Kwon TK, Park WS, Chang JS, Park SK, Ahn BH et al. Neoplastic transformation and tumorigenesis associated with overexpression of phospholipase D isozymes in cultured murine fibroblasts. Carcinogenesis 2001; 22: 1641-1647. (Pubitemid 32952141)
36. Knoepp SM, Chahal MS, Xie Y, Zhang Z, Brauner DJ, Hallman MA et al. Effects of active and inactive phospholipase D2 on signal transduction, adhesion, migration, invasion, and metastasis in EL4 lymphoma cells. Mol Pharmacol 2008; 74: 574-584.
37. Gozgit JM, Pentecost BT, Marconi SA, Ricketts-Loriaux RSJ, Otis CN, Arcaro KF. PLD1 is overexpressed in an ER-negative MCF-7 cell line variant and a subset of phospho-Akt-negative breast carcinomas. Br J Cancer 2007; 97: 809-817. (Pubitemid 47396281)
38. Kang DW, Lee SH, Yoon JW, Park WS, Choi KY, Min DS. Phospholipase D1 drives a positive feedback loop to reinforce the Wnt/beta-catenin/TCF signaling axis. Cancer Res 2010; 70: 4233-4242.
39. Kang DW, Min DS. Positive feedback regulation between phospholipase D and Wnt signaling promotes Wnt-driven anchorage-independent growth of colorectal cancer cells. PLoS ONE 2010; 5: e12109.
40. Kang DW, Choi KY, Min DS, Phospholipase D. Meets Wnt signaling: a new target for cancer therapy. Cancer Res 2011; 71: 293-297.
41. Murata-Kamiya N, Kurashima Y, Teishikata Y, Yamahashi Y, Saito Y, Higashi H et al. Helicobacter pylori CagA interacts with E-cadherin and deregulates the betacatenin signal that promotes intestinal transdifferentiation in gastric epithelial cells. Oncogene 2007; 26: 4617-4626. (Pubitemid 47067401)
42. Higashi H, Tsutsumi R, Muto S, Sugiyama T, Azuma T, Asaka M et al. SHP-2 tyrosine phosphatase as an intracellular target of Helicobacter pylori CagA protein. Science 2002; 295: 683-686. (Pubitemid 34111828)
43. Churin Y, Al-Ghoul L, Kepp O, Meyer TF, Birchmeier W, Naumann M et al. Helicobacter pylori CagA protein targets the c-Met receptor and enhances the mitogenic response. J Cell Biol 2003; 161: 249-255. (Pubitemid 36529844)
44. Wei J, Nagy TA, Vilgelm A, Zaika E, Ogden SR, Romero-Gallo J et al. Regulation of p53 tumor suppressor by Helicobacter pylori in gastric epithelial cells. Gastroenterology 2010; 139: 1333-1343.
45. Buti L, Spooner E, Van der Veen AG, Rappuoli R, Covacci A, Ploegh HL. Helicobacter pylori cytotoxin-associated gene A (CagA) subverts the apoptosis-stimulating protein of p53 (ASPP2) tumor suppressor pathway of the host. Proc Natl Acad Sci USA 2011; 108: 9238-9243.
46. Shibata W, Hirata Y, Maeda S, Ogura K, Ohmae T, Yanai A et al. CagA protein secreted by the intact type IV secretion system leads to gastric epithelial inflammation in the Mongolian gerbil model. J Pathol 2006; 210: 306-314. (Pubitemid 44660509)
47. Rieder G, Merchant JL, Haas R. Helicobacter pylori cag-type IV secretion system facilitates corpus colonization to induce precancerous conditions in Mongolian gerbils. Gastroenterology 2005; 128: 1229-1242. (Pubitemid 40712175)
48. Arakawa T, Watanabe T, Fukuda T, Yamasaki K, Kobayashi K. Rebamipide novel prostaglandin-inducer accelerates healing and reduces relapse of acetic acidinduced rat gastric ulcer: comparison with cimetidine. Dig Dis Sci 1995; 40: 2469-2472.
49. Yamane T, Nakatani H, Matsumoto H, Iwata Y, Kikuoka N, Takahashi T. Inhibitory effects of Rebamipide on ENNG induced duodenal carcinogenesis in mice: a possible strategy for chemoprevention of gastrointestinal cancers. Dig Dis Sci 1998; 43: S207-S211.
50. Oliveira MJ, Costa AC, Costa AM, Henriques L, Suriano G, Atherton JC et al. Helicobacter pylori induces gastric epithelial cell invasion in a c-Met and type IV secretion system-dependent manner. J Biol Chem 2006; 281: 34888-34896. (Pubitemid 46036528)
51. Peek Jr RM, Blaser MJ, Mays DJ, Forsyth MH, Cover TL, Song SY et al. Helicobacter pylori strain-specific genotypes and modulation of the gastric epithelial cell cycle. Cancer Res 1999; 59: 6124-6131. (Pubitemid 30035632)
52. Rudi J, Kuck D, Strand S, von Herbay A, Mariani SM, Krammer PH et al. Involvement of the CD95 (APO-1/Fas) receptor and ligand system in Helicobacter pyloriinduced gastric epithelial apoptosis. J Clin Invest 1998; 102: 1506-1514. (Pubitemid 28492217)
53. Jones NL, Day AS, Jennings HA, Sherman PM. Helicobacter pylori induces gastric epithelial cell apoptosis in association with increased Fas receptor expression. Infect Immun 1999; 67: 4237-4242. (Pubitemid 29357051)
54. Chen G, Sordillo EM, Ramey WG, Reidy J, Holt PR, Krajewski S et al. Apoptosis in gastric epithelial cells is induced by Helicobacter pylori and accompanied by increased expression of BAK. Biochem Biophys Res Commun 1997; 239: 626-632. (Pubitemid 27489016)
55. Snider JL, Cardelli JA. Helicobacter pylori induces cancer cell motility independent of the c-Met receptor. J Carcinog 2009; 8: 7.
56. Wang H, Sun Y, Liu S, Yu H, Li W, Zeng J et al. Upregulation of progranulin by Helicobacter pylori in human gastric epithelial cells via p38MAPK and MEK1/2 signaling pathway: role in epithelial cell proliferation and migration. FEMS Immunol Med Microbiol 2011; 63: 82-92.
57. Cover TL, Dooley CP, Blaser MJ. Characterization of and human serologic response to proteins in Helicobacter pylori broth culture supernatants with vacuolizing cytotoxin activity. Infect Immun 1990; 58: 603-610. (Pubitemid 20072620)
58. Mimuro H, Suzuki T, Tanaka J, Asahi M, Haas R, Sasakawa C. Grb2 is a key mediator of Helicobacter pylori CagA protein activities. Mol Cell 2002; 10: 745-755. (Pubitemid 35335631)
59. Dixon MF, Genta RM, Yardley JH, Correa P. Classification and grading of gastritis. The updated Sydney System. International Workshop on the Histopathology of Gastritis, Houston 1994. Am J Surg Pathol 1996; 20: 1161-1181.